Dapagliflozin attenuates progression from prefrailty to frailty in patients with hypertension and chronic kidney disease.
A kidney disease medication reduced older adults' risk of becoming frail by nearly 87%, suggesting physical decline isn't inevitable.
BACKGROUNDChronic kidney disease (CKD) and hypertension share common pathophysiological pathways contributing to vascular damage, endothelial dysfunction, and physical decline, particularly in older adults with prefrailty. In adjusted analyses, receiving dapagliflozin was independently associated with lower odds of progressing to frailty at 1 year (OR = 0,130, CI 0,045-0,381, P < 0,001),CONCLUSIONIn older hypertensive patients with CKD, greater renal injury is associated with worse physical performance, while dapagliflozin use reduces the risk of frailty progression.
What the study was
- Study design
- Clinical cohort study
- Population
- older adults
- Category
- Prevention
- Maturity
- Validated
- Journal
- The Journal of clinical investigation
Why it surfaced
Abstract-reviewed clinical cohort study scored conservatively for prevention; 7/10 reflects the available design, relevance, novelty, and population or unmet-need evidence.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.